|
|
Vaccine Detail
|
VSVΔG-MERS vaccine |
| Vaccine Information |
- Vaccine Name: VSVΔG-MERS vaccine
- Target Pathogen: MERS-CoV
- Target Disease: Middle East Respiratory Syndrome (MERS)
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: S from MERS-CoV (Liu et al., 2018)
- Immunization Route: Intramuscular injection (i.m.)
- Description: Chimeric virus based on the vesicular stomatitis virus (VSV) in which the G gene was replaced by MERS-CoV S gene (VSVΔG-MERS) (Liu et al., 2018)
|
| Host Response |
|
Macaque Response
- Vaccination Protocol: intramuscularly immunized with 2e7 FFU VSVΔG-MERS (preparation described below) in 2 ml medium via hind limb muscle injection or intranasally immunized with 2e7 FFU VSVΔG-MERS as via nostril instillation under anesthesia (Liu et al., 2018)
- Immune Response: recombinant virus induced high level of S protein specific IgG in both groups (Liu et al., 2018)
|
| References |
Liu et al., 2018: Liu R, Wang J, Shao Y, Wang X, Zhang H, Shuai L, Ge J, Wen Z, Bu Z. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral research. 2018; 150; 30-38. [PubMed: 29246504].
|
|
